UMB Bank n.a. Grows Stock Holdings in Hims & Hers Health, Inc. $HIMS

UMB Bank n.a. boosted its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 87.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,453 shares of the company’s stock after purchasing an additional 1,143 shares during the period. UMB Bank n.a.’s holdings in Hims & Hers Health were worth $122,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Hims & Hers Health by 24.2% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 15,638 shares of the company’s stock worth $750,000 after buying an additional 3,050 shares during the last quarter. Lake Hills Wealth Management LLC bought a new stake in shares of Hims & Hers Health during the 2nd quarter valued at about $277,000. Fiduciary Alliance LLC increased its position in shares of Hims & Hers Health by 120.4% during the 2nd quarter. Fiduciary Alliance LLC now owns 109,253 shares of the company’s stock valued at $5,446,000 after purchasing an additional 59,686 shares during the last quarter. Range Financial Group LLC bought a new position in shares of Hims & Hers Health in the 2nd quarter worth approximately $996,000. Finally, Webster Bank N. A. boosted its holdings in shares of Hims & Hers Health by 229.1% in the second quarter. Webster Bank N. A. now owns 905 shares of the company’s stock worth $45,000 after buying an additional 630 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $53.31 on Thursday. The company has a market capitalization of $12.05 billion, a price-to-earnings ratio of 66.64, a PEG ratio of 3.78 and a beta of 2.14. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The stock’s 50-day simple moving average is $50.97 and its 200-day simple moving average is $46.04. Hims & Hers Health, Inc. has a 52 week low of $16.05 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same period last year, the business posted $0.06 EPS. The firm’s revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 660,000 shares of the firm’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the transaction, the chief executive officer owned 2,214,769 shares in the company, valued at $112,023,016.02. This trade represents a 22.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 60,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total value of $3,214,800.00. Following the completion of the sale, the insider owned 169,940 shares in the company, valued at $9,105,385.20. This represents a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,535,562 shares of company stock valued at $78,305,856. Corporate insiders own 13.71% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of research reports. UBS Group set a $30.00 target price on shares of Hims & Hers Health in a report on Monday, June 23rd. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $68.00 target price on shares of Hims & Hers Health in a report on Friday, September 12th. Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $40.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Two investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $38.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.